Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Reports $12.7M First Quarter Loss

NEW YORK, April 23 -- Affymetrix had a net loss of $12.7 million on revenues of $66.8 million as it reported first-quarter 2003 earnings today. The loss ended a run of two straight quarters of profitability.

 

Affymetrix reported R&D expenses of $15.9 million for the quarter, compared to $16.7 million for the year-ago quarter.

 

The company said it sold 22 GeneChip microarray systems during the quarter, and reported revenues of $33.4 million on sales of its GeneChip microarrays, with another $2.5 million in revenue coming from wafer sales to Perlegen in revenues of $66.8 million, compared to $68.1 million in the year-ago first quarter. The company reported net income of $2.9 million for the fourth quarter on revenues of $69.7 million.

 

On April 3, Affymetrix issued an earnings warning, estimating its revenues for the first quarter to fall within a range of $60-$62 million. The stock market responded as Affymetrix's stock dropped from a closing price of $28.00 a share on April 3, to $18.33 at market close on April 4, a 35 percent loss. Three law firms filed shareholder lawsuits in response.

 

 

 

 

 

 

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.